Outcomes of Heart Failure Patients in Türkiye
Author Information
Author(s): ŞAHİN Anıl, YILMAZ Mehmet Birhan, ÇELİK Ahmet, ÇÖLLÜOĞLU İnci Tuğçe, URAL Dilek, ASARCIKLI Lale Dinç, NALBANTGİL Sanem, DEMİR Emre, ÇAVUŞOĞLU Yüksel, MURAT Selda, KANIK Emine Arzu, ATA Naim, ÜLGÜ Mustafa Mahir, BİRİNCİ Şuayip
Primary Institution: Scientific and Technological Research Council of Turkey (TUBITAK)
Hypothesis
This study aims to shed light on survival rates, potential influences of guideline-directed therapies, and sex-based differences necessitating personalized management in heart failure.
Conclusion
The survival rate of heart failure in Türkiye is similar to world data, with female patients showing better survival than male patients, likely due to the widespread use of guideline-directed therapies.
Supporting Evidence
- Out of 2,722,151 HF patients, the overall mortality rate was 33.7%.
- Survival rates at 1, 5, and 7 years after the HF diagnosis were detailed.
- Deceased HF patients had more comorbidities and higher natriuretic peptides.
Takeaway
This study looked at heart failure patients in Türkiye and found that women tend to live longer than men after being diagnosed, and many patients don't even need to go to the hospital.
Methodology
A nationwide retrospective cohort analysis using deidentified data from the Turkish Ministry of Health’s national electronic database.
Potential Biases
The retrospective nature of the data limits the ability to establish causal relationships.
Limitations
The study has potential biases related to the selection process and incomplete availability of echocardiography data.
Participant Demographics
The cohort included 2,701,099 adult patients with heart failure, with a median age of 66 for survivors and 77 for deceased patients.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI: 82.0–82.2 for males, 95% CI: 83.2–83.3 for females
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website